The Archive · 4 posts
Discover the future of healthcare! 🚀 Syncona Limited (SYNC) is leading life sciences investment on the LSE. 🌟
Syncona FY26: NAV flat at 170.6p, new investment policy and £250m return plan approved. Beacon Therapeutics leads portfolio gains. Strategic pivot to realise value for shareholders.
June 18, 2026
Showing 3 of 4 posts
Syncona's NAV grows 3.6% in Q3 2025, fueled by Beacon Therapeutics' $75M Series C. Key catalysts ahead for NAV growth and shareholder returns.
JoshuaFebruary 5, 2026
Syncona Q1 NAV up 0.5% to 171.8p driven by Autolus EU approval; clinical progress offsets FX headwinds.
JoshuaAugust 7, 2025
Syncona shifts to orderly realisations amid biotech market challenges, addressing 48.2% NAV discount & accelerating cash returns to shareholders.
JoshuaJune 19, 2025
June 19, 2025